Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association"

Breast. 2018 Jun:39:151-152. doi: 10.1016/j.breast.2018.03.003. Epub 2018 Mar 17.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Body Mass Index
  • Breast Neoplasms*
  • Humans
  • Receptor, ErbB-2
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab